QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Castagne, V. Articles by Farinotti, R. Search for Related Content PubMed PubMed Citation Articles by Castagne, V. Articles by Farinotti, R.

SHORT COMMUNICATION

EFFECT OF RECOMBINANT INTERLEUKIN-2 PRETREATMENT ON ORAL AND INTRAVENOUS DIGOXIN PHARMACOKINETICS AND P-GLYCOPROTEIN ACTIVITY IN MICE

Unité Propre de Recherche de l'Enseignement Supérieur, Faculté de Pharmacie, Chatenay-Malabry Paris XI France (V.C., M.B.R., M.S., R.F., F.G., L.B.F.); Service Pharmacie-Pharmacologie, Höpital Paul Brousse, Villejuif, France (V.C., L.B.F.); Laboratoire de Pharmacologie, Faculté de Médecine, Université Paris XII, Créteil, France (S.U.); and Service de pharmacie clinique et des biomatériaux, Höpital Bichat Claude Bernard, Paris, France (M.B.R., R.F.)

P-glycoprotein (P-gp) is an ATP-dependent efflux membrane transporter involved in many drug pharmacokinetics in humans. Decreasing its expression could enhance the bioavailability of substrates as digoxin. We have recently found that human recombinant interleukin-2 (rIL2) in vivo decreases P-gp expression in intestine and brain of mice and modifies oral digoxin pharmacokinetics. The aim of the study was to evaluate the involvement of bioavailability in the rIL2 pretreatment effect on digoxin pharmacokinetics by comparing oral and i.v. digoxin pharmacokinetics before and after rIL2 pretreatment (10 µg/kg). We also tried to show the possible effect of a low rIL2 dose (1 µg/kg) pretreatment on oral digoxin pharmacokinetics. First, adult Swiss mice received a single oral or i.v. dose of digoxin (0.03 mg/kg). Two weeks later, the same animals were treated by rIL2 i.p. twice a day (10 µg/kg) for 4 days and received digoxin again at day 5. As well, another group received oral digoxin (0.03 mg/kg) with a 1 µg/kg rIL2 pretreatment. Blood was collected after digoxin administration with and without rIL2 pretreatment. Digoxin pharmacokinetics were described by a one-compartment model. The 10 µg/kg rIL2 pretreatment did not modify i.v. digoxin pharmacokinetics, whereas oral digoxin pharmacokinetics were significantly modified by the 10 µg/kg rIL2 pretreatment and not by the 1 µg/kg rIL2 pretreatment. The decrease of P-gp activity, caused by rIL2 (10 µg/kg), increased digoxin bioavailability. An increase in exposure and intracellular level of drugs is expected from rIL2 pretreatment.